Skip to content

Efficacy of Nitric Oxide Administration for Reducing the Risk of Acute Kidney Injury and 90 day renal adverse events in Patients with Acute Type A Aortic Dissection: a Randomized Controlled Trial

Efficacy of Nitric Oxide Administration for Reducing the Risk of Acute Kidney Injury 90 day renal adverse events in Patients with Acute Type A Aortic Dissection: a Randomized Controlled Trial

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400087433
Enrollment
Unknown
Registered
2024-07-26
Start date
2024-08-01
Completion date
Unknown
Last updated
2024-07-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Kidney Injury, Acute Type A Aortic Dissection

Interventions

Intervention group:40 ppm nitric oxide was added from the start of intraoperative cardiopulmonary bypass to 24 h after surgery
control group:none

Sponsors

Beijing Anzhen Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Provide written informed consent; 2. Participants must be over 18 years of age; 3. Participants should meet the diagnostic and treatment guidelines for thoracic aortic diseases jointly issued by ACC/AHA in 2022, have received clinical and radiological diagnosis of acute type A aortic dissection, and undergone surgical thoracotomy within two weeks after symptom onset.

Exclusion criteria

Exclusion criteria: 1. missing baseline value or missing postoperative serum creatinine value (Scr); 2. preoperative eGFR less than 30ml/min/1.73 m2 or receive renal replacement therapy; 3. history of kidney disease, including glomerular diseases: acute glomerulonephritis, rapidly progressive glomerulonephritis, chronic glomerulonephritis, nephrotic syndrome, etc., secondary nephropathy: lupus nephritis, diabetic nephropathy, interstitial nephritis, renal tubular disease, chronic renal failure, renal replacement therapy, etc.; 4. previous renal tumor, kidney transplantation, and other related surgery; 5. patients with single kidney; 6. history of malignant tumor or received radiotherapy and chemotherapy; 7. severe skeletal muscle disease and autoimmune disease; 8. preoperative dissection rupture or hemodynamic instability (systolic blood pressure <90mmHg); 9. life expectancy less than 90 days; 10. pregnant and lactating women, patients with mental disorders; 11. with intravascular or extravascular hemolytic disease; 12. have participated in other clinical trials.

Design outcomes

Primary

MeasureTime frame
Acute kidney injury (AKI);

Secondary

MeasureTime frame
AKI severity;Urine volume during CPB and within 24 h after surgery;Dose of diuretics and recombinant human brain natriuretic peptide within 24 h after surgery;Oxygenation index and near-renal infrared oxygen saturation;free hemoglobin;methemoglobin ;Nitrite (NO2-);Nitrate (NO3-);Maximum severity of multiple organ failure (SOFA scale);Vasoactive-inotropic score (VIS);Duration of mechanical ventilation (hours);ICU stay (days);Hospital stay (days);CVP and PEEP;Major Adverse Kidney Events;

Countries

China

Contacts

Public ContactNan Liu

Intensive Care Unit B, Cardiac Surgical Critical Care Center, Beijing Anzhen Hospital

ln9102@126.com+86 136 0123 3702

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026